



Bayer AG  
Communications  
51368 Leverkusen  
Germany  
Phone +49 214 30-1  
[www.bayer.com/en/media](http://www.bayer.com/en/media)

## News Release

**Not intended for U.S. and UK Media**

---

### **Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions**

- AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity
  - Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow
  - Market introduction to start in US and several European countries
  - Strategically complements Bayer's comprehensive portfolio of contrast media, fluid delivery systems and digital management solutions
- 

**Berlin, June 28, 2022** – Bayer today announced the launch of Calantic™ Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging. The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer will expand its comprehensive portfolio beyond contrast media, medical devices, software and services. The new platform will support healthcare professionals at all stages of their work, from diagnosis through treatment of their patients.

“AI has the potential to transform healthcare, and particularly in medical imaging it can turn the growing amounts of data into value-adding insights to support radiologists and their teams in their decision-making”, said Dr. Ryan Lee, Chair, Department of Radiology, Einstein Healthcare Network, Philadelphia, USA. “It is crucial to drive innovation in this area and broaden access to digital tools that can help address the rising demand for solutions which improve the speed and accuracy of diagnoses.”

“As a leader in key Radiology areas and building on our deep medical understanding across a multitude of diagnostic and therapeutic areas, Calantic Digital Solutions

underlines our commitment to continue accelerating innovation for the benefit of patients and their physicians”, said Gerd Krueger, Head of Radiology, Bayer Pharmaceuticals. “With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams.”

Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which assist radiologists and their teams at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites’ workflow, and free up time for radiologists and their teams. The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO). ICH and LVO can be associated with stroke. More disease-specific application packages will be added moving forward. Bayer provides services around installation, configuration, and training of the platform and its applications. First launch markets will include the US and several European countries, with more regions to follow, upon local regulatory approvals as applicable.

### **About AI in Medical Imaging**

With global sales of €400m, radiology AI is the fastest growing market segment within the overall global radiology market. It is expected to continue growing dynamically, with an estimated compounded annual growth rate of more than 25 percent through 2025. Innovation powered by AI is more needed than ever: aging populations and changing lifestyles are leading to an increase in chronic conditions such as cardiovascular disease and cancer. Consequently, the demand for medical imaging to detect diseases, guide treatment decisions and support therapy planning is growing. AI comes with the value proposition to accelerate diagnosis and increase the throughput of radiological examinations.

This is particularly important because time pressure and workload contribute to the prevalence of burn-out among radiologists. Aggravating this situation, there is a shortage

of trained radiologists.<sup>1</sup> In addition, publications show that the rate of diagnostic errors rises with long hours of overtime: a publication from 2018 speaks of approximately 40 million diagnostic errors involving imaging worldwide every year.<sup>2</sup> Digital technologies can help manage the mounting workload of radiologists and their teams, ultimately striving to improve patient care.

### **About Radiology at Bayer**

Everyone deserves clear answers about their health, starting with an early and accurate diagnosis. As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to high-quality services. Bayer has a leading portfolio of contrast media for computed tomography (CT), X-Ray, and magnetic resonance imaging (MRI), devices for their precise administration, informatics solutions to support efficient and optimized patient care, as well as acknowledged educational programs that generated €1.8bn sales in 2021. Following the company's ambition to outperform the radiology market's average annual growth of 5% until 2030, Bayer is strongly committed to research and development, which includes leveraging artificial intelligence and driving innovation in medical imaging. Each of these offerings provide effective tools to support radiologists in their mission to deliver treatment critical answers and a clear direction – from diagnosis to care.

### **About Bayer**

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to [www.bayer.com](http://www.bayer.com).

---

<sup>1</sup> The Complexities of Physician Supply and Demand: Projections From 2018 to 2033. AAMC. <https://www.aamc.org/media/45976/download>; the Royal College of Radiology: Clinical Radiology UK workforce census report 2020: [https://www.rcr.ac.uk/system/files/publication/field\\_publication\\_files/clinical-radiology-uk-workforce-census-2020-report.pdf](https://www.rcr.ac.uk/system/files/publication/field_publication_files/clinical-radiology-uk-workforce-census-2020-report.pdf)

<sup>2</sup> Fundamentals of Diagnostic Error in Imaging, Itri et al. (2018) <https://pubs.rsna.org/doi/full/10.1148/rg.2018180021>

Contact for media inquiries:

**Victoria Vigener, phone +49 175 3093282**

Email: [victoria.vigener@bayer.com](mailto:victoria.vigener@bayer.com)

Contact for investor inquiries:

**Bayer Investor Relations Team, phone +49 214 30-72704**

Email: [ir@bayer.com](mailto:ir@bayer.com)

[www.bayer.com/en/investors/ir-team](http://www.bayer.com/en/investors/ir-team)

Find more information at <https://pharma.bayer.com/>

Follow us on Facebook: <http://www.facebook.com/bayer>

Follow us on Twitter: [@BayerPharma](https://twitter.com/BayerPharma)

vig (2022-0101E)

**Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.